-93%

est. 2Y upside i

HealthcareSeed

Computational antibody design

Rank

#3790

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Medium

This opportunity carries exceptionally high risk due to extremely limited funding, a drastically reduced team, and minimal revenue against a backdrop of well-funded competitors, making it suitable only for job seekers with a very high-risk tolerance who believe in a long-shot technological breakthrough.

Last updated: February 16, 2026

Bull (15%)+400%

A significant technological breakthrough or major partnership leads to an acquisition by a larger pharmaceutical or biotech company.

Base (35%)-20%

The company continues to operate at a minimal scale, securing minor contracts but failing to attract significant new funding or achieve a major exit within two years.

Bear (50%)-95%

The company fails to secure additional funding or significant partnerships, leading to a wind-down of operations or a fire sale of its intellectual property.

Est. time to liquidity~6.0 years

Community

Valuation Sentiment

Our model estimates -93% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.